Bibliography
- Rovner ES, Wein AJ, Caruso D. A woman's guide to regaining bladder control. In: Evans M, editor. Everything you need to know for the diagnosis and cure of incontinence. M evans and Company Incorporated, New York; 2002
- Herschorn S, Gajewski J, Schulz J, Corcos J. A population-based study of urinary symptoms and incontinence: the canadian urinary bladder survey. BJU Int 2008;101(1):52-8
- Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: aua/sufu guideline. J Urol 2012;188(6 Suppl):2455-63
- Basra R, Kelleher C. Disease burden of overactive bladder: quality-of-life data assessed using ici-recommended instruments. Pharmacoeconomics 2007;25(2):129-42
- Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997;26(5):367-74
- Weiss JP, Weinberg AC, Blaivas JG. New aspects of the classification of nocturia. Curr Urol Rep 2008;9(5):362-7
- Galizia G, Langellotto A, Cacciatore F, et al. Association between nocturia and falls-related long-term mortality risk in the elderly. J Am Med Dir Assoc 2012;13(7):640-4
- Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7(4):455-63
- Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012;1:CD005429
- Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189(4):1388-95
- Guay DR. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Pharmacotherapy 1999;19(3):267-80
- Detrol (Tolterodine L-Tartrate) Product Monograph. Pfizer Canada Inc., 17,300 Trans-Canada Highway. Kirkland Quebec h9j 2m5; February 10; 2010
- Malhotra BK, Glue P, Sweeney K, et al. Thorough qt study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007l;81(3):377-85
- Larsson G, Hallen B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase ii efficacy and safety data. Urology 1999;53(5):990-8
- Van Kerrebroeck PE, Amarenco G, Thuroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998;17(5):499-512
- DuBeau CE, Morrow JD, Kraus SR, et al. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. Neurourol Urodyn 2012;31(8):1258-65
- Hsiao SM, Chang TC, Wu WY, et al. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res 2011;37(8):1084-91
- Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999;161(5):1551-5
- Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50(6A Suppl):90-6; discussion 97-99
- Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother 2001;2(10):1685-701